[1] Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis, 2017, 21: 631-643.
[2] Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther, 2013,37: 647-652.
[3] Kontos MC, Lanfear DE, Gosch K, et al. Prognostic Value of Serial N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients With Acute Myocardial Infarction. Am J Cardiol,2017,120: 181-185.
[4] Oremus M, McKelvie R, Don-Wauchope A,et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev, 2014,19: 413-419.
[5] Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation, 2009,120: 2177-2187.
[6] Muthukumar S, Sadacharan D, Ravikumar K, et al. A prospective study on cardiovascular dysfunction in patients with hyperthyroidism and its reversal after surgical cure. World J Surg, 2016, 40: 622-628.
[7] Omura T, Yoshiyama M, Hayashi T, et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res, 2005,96: 148-150.
[8] Poller W, Kaya Z, Muche M,et al. High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection. Clin Res Cardiol, 2017, 106: 551-556.
[9] Demir C, Demir M. Effect of hepatitis C virus infection on the right ventricular functions, pulmonary arterypressure and pulmonary vascular resistance. Int J Clin Exp Med, 2014, 7: 2314-2318.
[10] 肖静,邹菁花,陈万. 血浆N末端B型利钠肽原水平评估肝硬化患者心功能改变及其与肝功能的关系.中华肝脏病杂志,2014, 22: 822-825.
[11] Okada K, Furusyo N, Ogawa E, et al. Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide.Endocrine, 2013,43: 200-205. |
